On June 18, 2010, the FDA Advisory Committee on Reproductive Health voted UNANIMOUSLY AGAINST flibanserin, the brain drug proposed by German manufacturer Boehringer-Ingelheim to treat hypoactive sexual desire disorder.

All of the speakers in the public part of the hearing who spoke against the drug were affiliated with the New View Campaign!! Our remarks focused on drug safety, legitimacy of the “hypoactive sexual desire disorder” diagnosis, the pre-launch marketing and medical education circus, and the need to situate women’s sexual desire in a broad psycho-sociocultural context respecting lifestage and cultural diversity. We brought a petiton signed by 650 people from 22 countries and 47 U.S. states, and Rachel Liebert twittered live from the hearing on the New View twitter page.

On our New View flibanserin page you can find our PETITION, our FINAL STATEMENT, all the FACT SHEETS and other resources.

Here are some photos that tell the tale. 

1) Team New View

2) the ballroom (Dan Davis, MD of the FDA is speaking)

3) Thea Cacchioni, sociology, UBC, speaks about "HSDD"

4) Karen Hicks speaks about adverse effects of flibanserin

5) Leonore Tiefer speaks about marketing and about our petition

6) Morgan Molnar, Lenore Pomerance and Rachel Liebert unfurl and display the 650 names on our petition

7) Amy Allina of National Women's Health Network 

8) Liz Canner speaks about marketing

9) Pharmed out students Antonie Meixel and Elena Yanchar speak about biases and conflicts of interest in Boehringer-Ingelheim CME courses

10) The final vote - 11-0 - the No's have it!!